• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip Launches 'Small Stocks, Big Money' Podcast

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email

    New podcast series shines a spotlight on undervalued small-cap and microcap stocks

    ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."

    Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing listeners with an insider perspective they won't find anywhere else.

    "Small Stocks, Big Money is not just a podcast. It's a mission to empower everyday investors by providing them with the knowledge and insights they need to discover potentially lucrative investment opportunities," said Gentry. "We're taking our 30 plus years of experience in the microcap space and sharing it with the world. Our vision is to shed light on these lesser-known companies that hold the potential to deliver substantial returns."

    Episodes of "Small Stocks, Big Money" are now available for streaming on major platforms including Spotify, Amazon, and Apple.

    The debut episodes of "Small Stocks, Big Money" feature Sharps Technology (NASDAQ:STSS), BullFrog AI (NASDAQ:BFRG), Zomedica (NYSE:ZOM), Lantern Pharma (NASDAQ:LTRN), and Reviva Pharmaceuticals (NASDAQ:RVPH).

    Listeners are encouraged to subscribe to the series to stay up-to-date with the latest episodes. Each installment promises to be a deep dive into the fast-paced world of microcap investing, offering unique insights that could shape the future of your investment portfolio.

    The "Small Stocks, Big Money" podcast series takes inspiration from the book of the same name written by Gentry. Published by Wiley, the book offers a unique perspective on microcap investing through a series of insightful interviews with small stock superstars. It provides readers with key lessons learned from successful investments and helps them understand how to discover promising companies, develop solid investment strategies, and navigate the risks associated with smaller companies. This wealth of knowledge now extends to the podcast, making it an invaluable resource for anyone interested in the world of small stocks and big money.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/771825/RedChip-Launches-Small-Stocks-Big-Money-Podcast

    Get the next $BFRG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG
    $LTRN
    $RVPH
    $STSS

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    Lantern Pharma Inc.
    $LTRN
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    Lantern Pharma Inc.
    $LTRN
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    Lantern Pharma Inc.
    $LTRN
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    7/26/2021$10.00Buy
    Maxim Group
    More analyst ratings

    $BFRG
    $LTRN
    $RVPH
    $STSS
    SEC Filings

    View All

    Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

    8/14/25 4:35:31 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    8/14/25 4:15:07 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    8/14/25 4:08:04 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine's path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc.

    8/14/25 4:25:11 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

    Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184, enabling advancement to upcoming Phase 1b/2 trials being planned for recurrent triple negative breast cancer (TNBC) and recurrent bladder cancer. Remarkable complete response observed in HARMONIC™ Trial patient: A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) demonstrated a co

    8/13/25 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

    Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ:LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at

    8/6/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

    ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    9/20/23 7:22:47 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

    The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

    6/8/23 7:41:12 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

    Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    1/6/23 9:00:39 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danner Paul K bought $100 worth of Series B Preferred Stock (5 units at $20.00) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    7/18/25 2:48:21 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    4/1/25 5:24:02 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

    4/A - Zomedica Corp. (0001684144) (Issuer)

    3/27/25 9:56:49 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Schalop Lee Troy

    3 - Lantern Pharma Inc. (0001763950) (Issuer)

    7/30/25 5:20:47 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Danner Paul K bought $100 worth of Series B Preferred Stock (5 units at $20.00) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    7/18/25 2:48:21 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Singh Vininder sold $43,625 worth of shares (29,002 units at $1.50), decreasing direct ownership by 1% to 2,292,446 units (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    7/8/25 5:55:24 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    12/20/24 7:00:00 AM ET
    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

    Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

    5/15/25 8:45:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

    Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

    5/8/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care